SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing a significant rally fueled by community buzz around a confirmed COEP merger involving 9,000 miners and reports of corporate treasuries accumulating DOGE, igniting fierce debate between those anticipating massive gains and others warning of a classic pump-and-dump.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending with significant community buzz around its upward price movement and potential decoupling from major cryptocurrencies, fueled by discussions of a short squeeze. While some anticipate further gains and institutional adoption, including growing interest from firms like Goldman Sachs, others foresee a retracement, all within the broader context of impending regulatory clarity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

The leveraged semiconductor ETF SOXL is seeing significant volatility as investors intensely debate whether its recent test of resistance marks a triple top signaling a potential sharp pullback, or if the ongoing AI super cycle and strong tech capital expenditures will propel the sector to new highs. The community remains sharply divided, with many actively trading its amplified movements while anticipating upcoming earnings from major chipmakers like AMD for directional cues.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors aggressively position for a market downturn, with many anticipating a significant correction in the tech-heavy Nasdaq due to concerns over overvalued AI stocks and increasing geopolitical tensions. The community is actively discussing a "bloodbath" for tech, leading to strong bullish sentiment for this inverse ETF as a hedge.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending following the official launch of its JasmyChain mainnet, an EVM-compatible L2 solution utilizing JASMY as a gas token for AI and Web3 applications. While many proponents emphasize this as a significant step for long-term utility and are actively accumulating, skeptics point to the continued lack of substantial positive price action, leading to heated debates about the project's legitimacy and future prospects.

Codatta

XNY Crypto is capturing attention as the community actively discusses its potential for a "next leg up" after recent significant rallies, noting its impressive resilience and strength even amid broader market volatility. While many see current levels as a strong buying opportunity for this AI/data utility token, its past volatility and rapid price movements remain a point of caution for some.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience.   The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency &lt;1 second. The chain currently supports 100k orders / second.  The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1.   The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

HYPE Crypto is garnering significant attention for its strong outperformance and resilience during broader crypto market weakness, with the community actively discussing its massive trading volumes and aggressive token buyback program. Many view it as a potential "safe haven" asset and "house of all finance" attracting both retail and institutional interest.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token is trending amidst significant token burns that drastically reduced supply and increasing demand for its private AI services, sparking bullish community expectations for a major breakout despite some concerns regarding market manipulation.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero Energy is a key focus as its specialized Gulf Coast refineries are poised to benefit from increased imports of Venezuelan heavy crude, a development enthusiastically discussed by the community for its potential to significantly enhance refining margins.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASP Isotopes Inc

ASP Isotopes is generating significant investor discussion following its Renergen acquisition and the anticipated QLE spin-off, a move many believe will unlock substantial value. While the community expresses frustration over consistent delays in isotope production and management's execution, institutional ownership continues to build, highlighting conviction in the company's long-term role in critical material supply chains for nuclear energy and AI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 437,896 shares, an...

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of...

Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 194,336 shares, a...

Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% - Here's Why

Repare Therapeutics (NASDAQ:RPTX) Shares Up 0.4% - Still a Buy...

Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw some unusual options trading on Wednesday. Stock investors bought 3,187 call options on the company. This represents an increase of 407...

Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.read more...

<ul class="summary-bullets"><li>The deal includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.</li><li>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta.</li><li>The treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.</li></ul>Repare Therapeutics Inc. (RPTX) shares soared more than 21% in Wednesday’s pre-market trade after the company announced a deal with Gilead Sciences Inc. (GILD) for its investigational cancer treatment.Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million. This includes an upfront payment of $25 million and an additional $5 million payment upon completion of specified technology transfer activities.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/RPTX">Repare Therapeutics</a> trended in the ‘extremely bullish’ territory at the time of writing.<a href="https://stocktwits.com/symbol/GILD">Gilead Sciences shares</a> were up around 1% in Wednesday’s pre-market trade. Retail sentiment around the company trended in the ‘neutral’ territory.<h2 class="st-heading-2">More About Repare’s Cancer Treatment</h2>Repare’s investigational cancer treatment, RP-3467, is a highly potent small-molecule inhibitor targeting polymerase theta. This is associated with BRCA mutations and other genomic alterations.A BRCA mutation is a harmful change in the BRCA1 or the BRCA2 genes that increases the risk for several cancers, including breast, ovarian, prostate, pancreatic, and others. This mutation is inherited and has no symptoms.Repare’s treatment is currently being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and preliminary activity.<h2 class="st-heading-2">Boosting Repare’s Cash Balance</h2>Repare stated that the Gilead deal has increased its cash balance, and it is the third portfolio deal entered into by the company this year.Following this deal, Repare estimates that its shareholders will receive $2.2 per share in the pending transaction with XenoTherapeutics Inc. Last month, XenoTherapeutics entered into a definitive agreement to acquire all the issued and outstanding common shares of Repare.Under the deal’s terms, Repare’s shareholders were expected to receive approximately $1.82 in cash per share, along with one non-transferable contingent value right (CVR) per common share. This CVR entitles holders to receive certain future cash payments over 10 years.<a href="https://stocktwits.com/symbol/RPTX">RPTX stock</a> is up 61% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/GILD">GILD stock</a> is up 34%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-stock-market-open-on-christmas-eve/cLesMeFREv2">Is The Stock Market Open Today? Here Are NYSE, Nasdaq Trading Hours On Christmas Eve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

Equity

Repare Therapeutics Announces Acquisition of Pol ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to...

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE...

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

Repare Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$2.65
Prev Close	$2.63
Open	$2.64
Dividend Yield	0.00%
50-Day Moving Average	$2.43
Beta	1.02
Avg. Volume	924,219.75
PE Ratio	-1.56

52-Week High	$2.66
52-Week Low	$0.89
Market Capitalization	$114.24M
EPS (Annual)	-$2.00
Price to Book	0.99
Revenue Per Employee	$414,550.39

RPTX
Repare Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RPTX News

RPTXRepare Therapeutics Inc